Overview
Dengue hemorrhagic fever (DHF), particularly grade III, represents a severe manifestation of dengue virus infection characterized by increased vascular permeability and hemorrhagic complications. Brazil has emerged as a significant epicenter for dengue, accounting for approximately 61% of global cases reported to the World Health Organization (WHO) in recent years [PMID:24626308]. The epidemiology highlights a notable shift towards younger age groups, with children between 5 and 15 years being disproportionately affected [PMID:24986196]. This shift underscores the evolving nature of dengue epidemiology and the need for heightened vigilance in pediatric populations. Clinicians must be adept at recognizing early signs of severe disease to implement timely interventions and mitigate complications.
Epidemiology
In the 21st century, Brazil has become a focal point for dengue virus transmission, reporting a substantial proportion—approximately 61%—of global dengue cases to the WHO [PMID:24626308]. This high burden underscores the country's vulnerability to dengue outbreaks and highlights the importance of robust surveillance systems. Epidemiological studies further reveal that children aged 5 to 15 years are disproportionately affected, with a notable outbreak study identifying 81 children diagnosed during a peak period [PMID:24986196]. This demographic trend suggests that pediatric populations are particularly susceptible, necessitating tailored public health strategies and clinical preparedness in this age group. Additionally, there is evidence of a progressive reduction in the age of patients affected by DHF, indicating evolving patterns that require continuous monitoring and adaptation of preventive measures [PMID:24626308].
Clinical Presentation
The clinical presentation of dengue hemorrhagic fever grade III is marked by a rapid progression and severe systemic involvement. Historically, Brazil has observed a concerning trend towards younger patients being affected by DHF, reflecting changes in disease epidemiology [PMID:24626308]. In hospitalized patients, those classified with DHF grades II, III, and IV exhibit significantly higher daily severity scores (≥12) from the early stages of illness, indicative of severe manifestations such as shock and hemorrhage [PMID:31725549]. Common presenting symptoms in pediatric patients include vomiting (60.5%), abdominal pain (32%), headache (30.9%), myalgia (23.5%), and bleeding manifestations (16%) [PMID:24986196]. These symptoms collectively signal the transition from uncomplicated dengue fever to severe forms, emphasizing the need for vigilant monitoring and early intervention to prevent progression to life-threatening complications.
Diagnosis
Diagnosing dengue hemorrhagic fever grade III accurately remains challenging due to the nuanced criteria outlined in the WHO 1997 classification system, which often fails to capture the full spectrum of severe disease manifestations [PMID:24626308]. Traditional diagnostic markers such as dengue NS1 antigen, IgM, and IgG antibodies provide valuable insights but have limitations in specificity and sensitivity. For instance, NS1 antigen was positive in 66.7% of cases, while IgM and IgG were detected in 29.6% and 18.5% of cases, respectively [PMID:24986196]. To address these challenges, the daily dengue severity score has emerged as a practical tool for clinicians. This scoring system, validated across various grades of dengue severity, offers a reliable method to monitor disease progression and predict severe outcomes in pediatric and adolescent patients with high sensitivity (86%) and specificity (84%) for assessing dengue shock syndrome [PMID:31725549]. Integrating such clinical scoring systems into routine practice can significantly enhance diagnostic accuracy and patient management.
Management
The management of dengue hemorrhagic fever grade III involves a multifaceted approach aimed at stabilizing the patient and mitigating complications. Brazil adopted the category "dengue with complications" (DWC) in 2001, which includes specific complications such as neurological manifestations, cardiac dysfunction, and severe thrombocytopenia, reflecting a more nuanced approach to categorizing severe cases [PMID:24626308]. In clinical practice, early recognition of severe disease through tools like the daily severity score is crucial. For instance, a score ≥12 has demonstrated high sensitivity and specificity in identifying patients at risk of dengue shock syndrome, guiding timely fluid resuscitation and hemodynamic support [PMID:31725549]. Supportive care remains central, encompassing fluid management to prevent hypovolemic shock, close monitoring of vital signs, and addressing specific complications such as bleeding and organ dysfunction. Antiviral therapies are currently limited, with management primarily focused on symptomatic relief and supportive care to stabilize the patient until the immune response subsides.
Complications
Severe dengue cases, including grade III DHF, are associated with a constellation of life-threatening complications that significantly impact patient outcomes. Ascites (48.1%), pleural effusion (39.5%), hepatomegaly (51.9%), gall bladder wall thickening, and abnormal liver function tests (33.3%) are notably more prevalent in these patients [PMID:24986196]. These complications reflect the systemic nature of dengue infection, particularly the involvement of multiple organ systems due to increased vascular permeability and coagulopathy. Clinicians must be vigilant for these signs, as they often necessitate specialized interventions such as paracentesis for ascites management or monitoring for respiratory distress secondary to pleural effusions. Early identification and management of these complications are critical to improving patient prognosis and reducing mortality rates.
Prognosis & Follow-up
The prognosis for patients with dengue hemorrhagic fever grade III varies but is generally guarded, especially in the absence of timely and appropriate interventions. A retrospective analysis of 81 pediatric patients with serologically confirmed dengue infection revealed a mortality rate of 2.5%, with severe dengue cases comprising 24.7% of the cohort [PMID:24986196]. This underscores the potential severity of the disease, particularly in vulnerable populations. Post-discharge follow-up is essential to monitor for delayed complications such as chronic liver disease or persistent thrombocytopenia. Regular clinical assessments, laboratory monitoring, and patient education on recognizing signs of relapse or secondary infections are crucial components of long-term management. Ensuring comprehensive follow-up care helps in early detection and management of any lingering health issues, thereby improving overall patient outcomes.
Key Recommendations
These recommendations aim to streamline clinical practice, improve patient outcomes, and mitigate the impact of severe dengue hemorrhagic fever in affected populations.
References
1 Cavalcanti LP, Mota LA, Lustosa GP, Fortes MC, Mota DA, Lima AA et al.. Evaluation of the WHO classification of dengue disease severity during an epidemic in 2011 in the state of Ceará, Brazil. Memorias do Instituto Oswaldo Cruz 2014. link 2 Tangnararatchakit K, Chuansumrit A, Watcharakuldilok P, Apiwattanakul N, Lertbunrian R, Keatkla J et al.. Daily Dengue Severity Score to Assess Severe Manifestations. The Pediatric infectious disease journal 2020. link 3 Sahana KS, Sujatha R. Clinical profile of dengue among children according to revised WHO classification: analysis of a 2012 outbreak from Southern India. Indian journal of pediatrics 2015. link